GlassScriptPhysician profile
Kamrun Naher
NPI 1578723110
$15,588.84
in general payments reported to CMS, 2019-2025
53 companies · $2,175 in 2025
The $2,175 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,941 · 2020: $1,585 · 2021: $1,848 · 2022: $2,652 · 2023: $2,662 · 2024: $2,726 · 2025: $2,175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,559 · Education: $3.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,559.31 |
| Education | $3.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,984.97 | 2019-2025 | Repatha, Otezla, Evenity |
| Astrazeneca Pharmaceuticals LP | $2,409.17 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $1,340.34 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,280.41 | 2020-2025 | Caplyta |
| Glaxosmithkline, LLC. | $890.74 | 2019-2025 | Trelegy Ellipta, Bexsero, Pediarix |
| Lilly USA, LLC | $690.24 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $628.29 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $607.88 | 2022-2025 | |
| Abbvie INC. | $543.79 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $498.77 | 2020-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Merck Sharp & Dohme LLC | $478.04 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Lundbeck LLC | $377.60 | 2021-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $313.57 | 2024-2025 | Xifaxan |
| Pfizer INC. | $271.32 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $224.79 | 2023-2025 | Evkeeza, Dupixent, Praluent |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kamrun Naher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.